{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:29:03Z","timestamp":1786768143105,"version":"build-2736575974"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,15]]},"DOI":"10.2169\/internalmedicine.6497-25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T22:08:40Z","timestamp":1767305320000},"page":"2175-2181","source":"Crossref","is-referenced-by-count":0,"title":["Sofosbuvir\/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings"],"prefix":"10.2169","volume":"65","author":[{"given":"Hitomi","family":"Takada","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Toshimori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Maebashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitomi","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Murohisa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Ashikaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Masuda Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Otsu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Marusawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Urawa","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Ise Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Takatsuki Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Oita Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Akahane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Ishinomaki Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Kusakabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Nonogi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokushima Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Imado","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Matsue Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Nasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yokohama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tottori Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kubotsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karatsu Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Akita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology 76: 139-154, 2022.","DOI":"10.1002\/hep.32341"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Higuchi M, Tamaki N, Kurosaki M, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther 55: 292-301, 2022.","DOI":"10.1111\/apt.16745"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zhou DQ, Liu JY, Zhao F, et al. Risk factors for hepatocellular carcinoma in cirrhosis: a comprehensive analysis from a decade-long study. World J Gastrointest Oncol 16: 4625-4635, 2024.","DOI":"10.4251\/wjgo.v16.i12.4625"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Premkumar M, Dhiman RK, Duseja A, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program. Gastroenterology 167: 1429-1445, 2024.","DOI":"10.1053\/j.gastro.2024.08.018"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lv GJ, Ji D, Yu L, et al.; APASL Viral Elimination Task force. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatol Int 18: 1459-1471, 2024.","DOI":"10.1007\/s12072-024-10700-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol 93: 6247-6256, 2021.","DOI":"10.1002\/jmv.27157"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tahata Y, Sakamori R, Yamada R, et al.; Osaka Liver Forum. Improved liver function after sustained virologic response enhanced prognosis in hepatitis C with compensated advanced liver fibrosis. Dig Dis Sci 68: 2115-2122, 2023.","DOI":"10.1007\/s10620-022-07629-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 50: 791-816, 2020.","DOI":"10.1111\/hepr.13503"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Feld JJ, Jacobson IM, H\u00e9zode C, et al.; the ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373: 2599-2607, 2015.","DOI":"10.1056\/NEJMoa1512610"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jacobson IM, Bourgeois S, Mathurin P, et al. The tolerability of sofosbuvir\/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: a pooled safety analysis. J Viral Hepat 30: 448-454, 2023.","DOI":"10.1111\/jvh.13814"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Hiraoka A, Michitaka K, Kumada T, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 6: 325-336, 2017.","DOI":"10.1159\/000479984"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Curry MP, O'Leary JG, Bzowej N, et al.; the ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373: 2618-2628, 2015.","DOI":"10.1056\/NEJMoa1512614"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol 56: 67-77, 2021.","DOI":"10.1007\/s00535-020-01733-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Liu CH, Chen PY, Chen JJ, et al. Sofosbuvir\/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. Hepatol Int 15: 338-349, 2021.","DOI":"10.1007\/s12072-021-10158-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liu CH, Chen CY, Su WW, et al. Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 71: 176-184, 2022.","DOI":"10.1136\/gutjnl-2020-323569"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pokorska-\u015apiewak M, Talarek E, Aniszewska M, et al. Efficacy and safety of treatment with sofosbuvir\/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study. Liver Int 43: 1871-1878, 2023.","DOI":"10.1111\/liv.15637"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Alem SA, Eletreby R, Abdellatif Z, et al. Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. Eur J Gastroenterol Hepatol 33: e746-e752, 2021.","DOI":"10.1097\/MEG.0000000000002240"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Caviglia GP, Troshina G, Santaniello U, et al. Long-term hepatocellular carcinoma development and predictive ability of non-invasive scoring systems in patients with HCV-related cirrhosis treated with direct-acting antivirals. Cancers (Basel) 14: 828, 2022.","DOI":"10.3390\/cancers14030828"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Itakura J, Kurosaki M, Kakizaki S, et al. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Rep 2: 100138, 2020.","DOI":"10.1016\/j.jhepr.2020.100138"},{"key":"21","unstructured":"21. Howe AYM, Rodrigo C, Cunningham EB, et al.; SHARED Collaborators. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep 4: 100462, 2022."},{"key":"22","unstructured":"22. Bhattacharya D, Aronsohn A, Price J, Lo Re V; the American Association for the Study of Liver Diseases-Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis ciad319, 2023."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12: 356-367, 2018.","DOI":"10.1007\/s12072-018-9878-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zar\u0119bska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, et al. Effectiveness and safety of pangenotypic regimens in the most difficult to treat population of genotype 3 HCV infected cirrhotics. J Clin Med 10: 3280, 2021.","DOI":"10.3390\/jcm10153280"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kondili LA, Gaeta GB, Brunetto MR, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network. PLoS One 12: e0185728, 2017.","DOI":"10.1371\/journal.pone.0185728"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wiktor S. How feasible is the global elimination of HCV infection? Lancet 393: 1265-1267, 2019.","DOI":"10.1016\/S0140-6736(18)32750-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol 8: 332-342, 2023.","DOI":"10.1016\/S2468-1253(22)00386-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ko K, Akita T, Satake M, Tanaka J. Epidemiology of viral hepatitis C: road to elimination in Japan. Glob Health Med 3: 262-269, 2021.","DOI":"10.35772\/ghm.2021.01069"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6497-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:11:49Z","timestamp":1786767109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6497-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6497-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"article-number":"6497-25"}}